abstract
- DNMT3A mutations in polycythemia vera (PV) patients were heterogenous and not enriched in interferon-alpha (IFN)-treated patients. DNMT3A mutations had no detectable impact on hematologic response, molecular response or survival outcomes.
DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera.
Academic Article
Overview
authors
publication date
- April 15, 2025
published in
- Blood Journal
Identity
Digital Object Identifier (DOI)
- 10.1182/blood.2024027528
PubMed ID
- 40233320